Logo

NEWSBRIEF: Gene Logic Reports Widened Revenue, Narrowed Loss, Contracted R&D in Q1

Apr 29, 2002

NEW YORK, April 29 - Gene Logic today reported wider revenue and a narrower first-quarter loss as it racked up more pharma and biotech subscribers.

Revenue for the period ended March 31 rose to $11.8 million from $8.2 million, and net loss narrowed to $7.5 million, or $.28 a share, from $10.6 million, or $.40 per share, one year ago.

 

R&D spending contracted in the quarter to $14.3 million from $15.7 million in the year-ago period, Gene Logic said. The company's bank account saw a boost, growing to $185 million as of March 31 compared with $128 million as of the same time last year.

 

For more information, readers may click here. A conference call is scheduled for 10:00 a.m. Eastern time.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.